TalkMed Group (5G3) Stock Overview
An investment holding company, provides medical oncology, stem cell transplants, palliative care, and other related services in Singapore, China, Hong Kong, Vietnam, New Zealand, Australia, and the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 6/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 5G3 from our risk checks.
5G3 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
TalkMed Group Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | S$0.46 |
| 52 Week High | S$0.50 |
| 52 Week Low | S$0.38 |
| Beta | 0.035 |
| 1 Month Change | 3.41% |
| 3 Month Change | 3.41% |
| 1 Year Change | 8.33% |
| 3 Year Change | 16.67% |
| 5 Year Change | 4.60% |
| Change since IPO | 10.98% |
Recent News & Updates
Shareholder Returns
| 5G3 | SG Healthcare | SG Market | |
|---|---|---|---|
| 7D | 0% | 0.5% | 1.3% |
| 1Y | 8.3% | -1.3% | 16.2% |
Return vs Industry: 5G3 exceeded the SG Healthcare industry which returned -1.3% over the past year.
Return vs Market: 5G3 underperformed the SG Market which returned 16.2% over the past year.
Price Volatility
| 5G3 volatility | |
|---|---|
| 5G3 Average Weekly Movement | 2.4% |
| Healthcare Industry Average Movement | 8.6% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in SG Market | 15.1% |
| 10% least volatile stocks in SG Market | 2.4% |
Stable Share Price: 5G3 has not had significant price volatility in the past 3 months compared to the SG market.
Volatility Over Time: 5G3's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 235 | Peng Tiam Ang | www.talkmed.com.sg |
TalkMed Group Limited, an investment holding company, provides medical oncology, stem cell transplants, palliative care, and other related services in Singapore, China, Hong Kong, Vietnam, New Zealand, Australia, and the United States. It operates in two segments: Oncology Services; and Cellular and Gene Therapy Related Products and Services. The company offers medical oncology services in the areas of breast, colon, lung, liver, biliary and pancreatic, gastro-intestinal, head and neck, genitourinary and gynaecological, and haematology malignancies and brain cancers, as well as lymphoma and leukaemia.
TalkMed Group Limited Fundamentals Summary
| 5G3 fundamental statistics | |
|---|---|
| Market cap | S$605.28m |
| Earnings (TTM) | S$43.79m |
| Revenue (TTM) | S$78.18m |
Is 5G3 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 5G3 income statement (TTM) | |
|---|---|
| Revenue | S$78.18m |
| Cost of Revenue | S$33.44m |
| Gross Profit | S$44.74m |
| Other Expenses | S$946.00k |
| Earnings | S$43.79m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.033 |
| Gross Margin | 57.22% |
| Net Profit Margin | 56.01% |
| Debt/Equity Ratio | 5.6% |
How did 5G3 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/07/11 01:27 |
| End of Day Share Price | 2025/07/10 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
TalkMed Group Limited is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Siew Khee Lim | CGS International |
| Jarick Seet | RHB Investment Bank |